Humanized immunoglobulins
    1.
    发明申请
    Humanized immunoglobulins 审中-公开
    人源化免疫球蛋白

    公开(公告)号:US20080160018A1

    公开(公告)日:2008-07-03

    申请号:US11603273

    申请日:2006-11-20

    摘要: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

    摘要翻译: 提供了具有一个或多个互补决定区(CDR)和来自供体免疫球蛋白的可能的附加氨基酸和来自接受人免疫球蛋白的框架区的人源化免疫球蛋白的生产和组合物的新方法。 除了CDR之外,每个人源化免疫球蛋白链通常还包含来自供体免疫球蛋白框架的氨基酸,例如能够与CDR相互作用以产生结合亲和力,例如一个或多个氨基酸,其紧邻于 供体免疫球蛋白中的CDR或通过分子建模预测的那些。 重链和轻链各自可以通过使用各种位置标准中的任何一个或全部来设计。 当组合成完整的抗体时,本发明的人源化免疫球蛋白在人体中将基本上是非免疫原性的,并且保留与抗原例如含有表位的蛋白质或其它化合物基本上与供体免疫球蛋白相同的亲和力。

    Process for producing PGE.sub.2 from PGA.sub.2
    9.
    发明授权
    Process for producing PGE.sub.2 from PGA.sub.2 失效
    制备PGE {HD 2 {B从PGA {HD 2

    公开(公告)号:US3948981A

    公开(公告)日:1976-04-06

    申请号:US534008

    申请日:1974-12-18

    摘要: Novel methods are disclosed for transforming PGA.sub.2 and 15.beta.-PGA.sub.2 and their acetates, methyl esters, and acetate methyl esters to various prostanoic acids and esters of the PGE.sub.2 and PGF.sub.2.sub..alpha. series. Some of the latter are novel and are useful for the same pharmacological purposes as PGE.sub.2 and PGF.sub.2.sub..alpha..

    摘要翻译: 公开了用于将PGA2和15β-PGA2及其乙酸酯,甲酯和乙酸甲酯转化为PGE2和PGF2α系列的各种前列腺酸和酯的新方法。 后者中的一些是新颖的,并且可用于与PGE2和PGF2α相同的药理学目的。

    11.beta.-PGF.sub.2.sub..beta. compounds
    10.
    发明授权
    11.beta.-PGF.sub.2.sub..beta. compounds 失效
    11 {62 -PGF {HD 2 {331 {0 {L compounds

    公开(公告)号:US3931283A

    公开(公告)日:1976-01-06

    申请号:US486373

    申请日:1974-07-08

    CPC分类号: C07C405/00 Y02P20/582

    摘要: Novel methods are disclosed for transforming PGA.sub.2 and 15.beta.-PGA.sub.2 and their acetates, methyl esters, and acetate methyl esters to various prostanoic acids and esters of the PGE.sub.2 and PGF.sub.2.sub..alpha. series. Some of the latter are novel and are useful for the same pharmacological purposes as PGE.sub.2 and PGF.sub.2.sub..alpha..

    摘要翻译: 公开了用于将PGA2和15β-PGA2及其乙酸酯,甲酯和乙酸甲酯转化为PGE2和PGF2α系列的各种前列腺酸和酯的新方法。 后者中的一些是新颖的,并且可用于与PGE2和PGF2α相同的药理学目的。